Effect of kombucha intake on the gut microbiota and obesity-related comorbidities: A systematic review
Mirian Aparecida de Campos Costa, Darlene Larissa de Souza Vilela, Gabriela Macedo Fraiz, Isabelle Lima Lopes, Ana Íris Mendes Coelho, Luíza Carla Vidigal Castro, José Guilherme Prado Martin
Abstract
Kombucha is a fermented nonalcoholic tea-based beverage produced through a symbiotic culture of bacteria and yeasts. In vitro studies have demonstrated antimicrobial, antioxidant, antiproliferative, and anti-carcinogenic properties of kombucha. However, no systematic reviews have evaluated the effects of kombucha in vivo. Thus, we aimed to evaluate the evidence that exists so far about kombucha consumption on comorbidities associated with obesity as well as on the gut microbiota. The search was conducted in accordance with PRISMA and the protocol was registered in PROSPERO (registration number: CRD42020158917). The MEDLINE/PubMed, Web of Science, LILACS, SciELO, Scopus, and Science Direct databases were used in the search considering the following terms: “kombucha” OR “kombucha tea” OR “kombucha teas” OR “tea, kombucha” OR “teas, kombucha” NOT “review.” Fifteen studies were included in this review. The results suggest that kombucha consumption attenuates oxidative stress and inflammation, improves the liver detoxification process, and reduces intestinal dysbiosis. There is evidence that kombucha consumption is beneficial for the control and treatment of obesity and associated comorbidities, as well as for the modulation of the gut microbiota in vivo.